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R andom ized  P h ase  III Tria l of E d a tr e x a te  V ersu s  
M ethotrexate  in  P atien ts  W ith M e ta s ta t ic  and/or  
R ecurrent Squam ous Cell C arcinom a of the  H ead  and  
Neck: A E u rop ean  O rgan izat ion  for R esea rch  and  
Treatm ent o f  Cancer Head and N eck  C ancer
C oop erat ive  Group Study
By J.H. Schornagel, J. Verweij, P.H.M. de Mulder, F. Cognetli, J.B. Vermorken, P. Cappelaere, J.P. Armand,
J. Wildiers, A. de GraefF, M. Clavel, T. Sahmoud, A. Kirkpatrick, and J.L Lefebvre
Purpose: To compare the response rates and the tox- 
icity of the new antifolate edatrexate (EDX) with that of 
methotrexate (MTX) in a randomized trial in patients with 
metastatic or recurrent squamous cell cancer of the head 
and neck (SCC) and to compare the durations of response 
and survival.
Patients and Methods: Two hundred seventy~three 
patients with SCC were randomized to receive either EDX 
or MTX as a weekly intravenous (IV) bolus injection. 
Doses of EDX were initially 80 m g /m V w k, but because 
of the toxicity, this was later reduced to 70 m g/m 2/w k . 
MTX was administered at a dose of 40 m g /m V w k  
throughout. In both arms, two dose increments of 10% 
were scheduled in case of no toxicity.
Results: Of 264 eligible patients, 131 were treated 
with EDX and 133 with MTX. There were five treatment- 
related deaths: four on EDX and one on MTX. Overall, 
toxicity was similar in both arms; however, stomatitis, 
skin toxicity, and hair loss were more pronounced on the 
EDX arm. The overall response rate was 21% (six
complete responses [CRs] and 21 partial responses [PRs]) 
for EDX and 16% (nine CRs and 12 PRs) for MTX (P « 
.392). Responses were mainly seen in patients with lo- 
coregiona! disease. Tumors that originated from the hy- 
popharynx responded poorly in comparison to tumors 
from other sites. The median duration of response was 
6.1 months for EDX and 6.4  months for MTX (log-rank P 
= .262). There was no difference in overall or progres­
sion-free survival. The median survival duration was 6 
months on both treatment groups.
Conclusion: Both EDX and MTX are moderately active 
against SCC. In this large phase III study, response rates, 
time to treatment failure, and overall survival appeared 
to be similar for both antifolates* However, EDX had 
more side effects than MTX and therefore cannot be rec­
ommended for routine palliative treatment of patients 
with SCC,
J Clin Oncol 13:1649-1655. © / 995 by American So­
ciety of Clinical Oncology.
HEMOTHERAPY of metastatic or recurrent squa­
mous cell cancer of the head and neck (SCC) con­
tinues to be disappointing. Drugs with documented activ­
ity include methotrexate (MTX), cisplatin, bleomycin and 
fluorouracil (5-FU).1 Combination chemotherapy regi-
in non-small-cell lung cancer and breast cancer.6 This 
activity was borne out in subsequent phase II studies.'7-9
In 1988, the European Organization for Research and 
Treatment of Cancer (EORTC) Head and Neck Cancer 
Cooperative Group initiated a randomized phase II trial 
mens produce higher response rates and more toxicity of EDX versus MTX in patients with SCC. A response
rate of 24% (complete responses [CRs] plus partial re-than single-agent treatment, but offer no advantage in 
terms of survival.10 Until now, MTX has been considered
the standard treatment for recurrent disease, as it is easy 
to administer and has a 20% to 40% response rate with 
acceptable toxicity.1,2 However, the median duration of 
response is invariably short, which underlines the need 
for more efficacious compounds in this disease. .10-Ethyl- 
10-deaza-aminopterin (edatrexate; EDX) is a new struc­
tural analog of MTX, which was developed through 
collaborative research at the Memorial Sloan-Kettering 
Cancer Center in New York and at the Stanford Research 
Institute International.4"6 It has more favorable cell mem­
brane characteristics than MTX, is a better substrate for 
polyglutamylation, and is a more potent inhibitor of the 
target enzyme, dihydrofolate reductase.4,5 In all preclini- 
cal models, EDX appeared to have superior antitumor 
activity as compared with MTX and a similar pattern of 
toxicity.4,5 In the phase I study, activity was observed
sponses [PRs]) for EDX among the first 44 patients
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treated has been reported elsewhere.10 Because EDX ap­
peared to be active in SCC, it was decided to continue 
the randomized phase II study as a  phase III trial to detect 
a possibly significant difference between EDX and MTX. 
We now report the results of the completed phase III trial 




Patients were eligible for this study if  they had measurable or 
assessable metastatic or recurrent SCC, for which no locoregional 
treatment was available. Prior chemotherapy for metastatic or recur­
rent disease was not allowed. However, patients were still eligible 
if they had received induction chemotherapy with cisplatin and 5- 
FU or bleomycin before locoregional treatment more than 1 year 
prior to study entry. Patients had to be less than 75 years of age, a 
Karnofsky score of >  50, a W BC count more than 4,000/^uL and a 
platelet count more than 100,000//jL, a serum creatinine concentra­
tion <  120 jumoJ/L or a creatinine clearance s  60 mL/min, adequate 
liver function tests, no CNS metastases, no third-space fluids, no 
acute illness or overt infectious disease, and no prior or concomitant 
second malignancy. Informed consent was obtained from all patients 
according to policies followed by individual participating institu­
tions. Patients were randomized to receive either EDX or MTX.
Chemotherapy and Criteria fo r  Evaluation o f  Toxicity 
and Response
EDX was administered every week at a dose of 80 mg/m1 as a 
rapid intravenous (IV) push injection. MTX was administered at a 
weekly dose of 40 mg/m2, also as a rapid IV push injection. After 
120 patients had been randomized, the starting dose of EDX was 
reduced to 70 mg/m2 because of serious toxicity, including three 
treatment-related deaths, Two dose increments of 10% were sched­
uled for both drugs if there was no toxicity after 2 weeks of treatment. 
Treatment was delayed until recovery in case o f  & grade 2 myelo- 
suppression or =s grade 1 mucositis, or an increase in serum creati­
nine concentration, and was subsequently resumed at reduced dos­
age. Toxicity was scored weekly and is given as worst grade 
observed during treatment per patient; response assessment was per­
formed every 4 weeks. Full blood counts and serum creatinine were 
measured weekly, other biochemistry measurements were performed 
every 4 weeks. To be assessable for response, patients had to have 
received at least four injections of the drug. Criteria for measurable 
and assessable disease and for the assessment of response were 
standard World Health Organization/International Union Against 
Cancer (WHO/UICC) criteria.11 Briefly, a CR was defined as the 
disappearance of all clinically detectable malignant disease for at 
least 4 weeks. A PR was defined as a ^  50% decrease in the sum 
of the products of all diameters o f  measured lesions for a minimum 
of 4 weeks without the appearance of new lesions. Stable disease 
(SD) was defined as a less than 50% regression or less than 25% 
increase in the sum of diameters for a minimum of 4 weeks without 
the appearance of new lesions. Progression was defined as a more 
than 25% increase in the size of any malignant lesion or the appear­
ance of any new lesion. CR duration was defined as the time elapsed 
from the date CR was first documented to the date on which disease 
progression was first noted. PR duration was defined as the time
between the first day o f  treatment and the date on which subsequent 
progressive disease was first noted. Standard WHO criteria were 
used for toxicity assessment,11
Statistical Design
The objectives of the study were to evaluate the response rate of 
weekly EDX as compared with that of weekly MTX in equitoxic doses 
in patients with SCC, to compare the duration of response and survival, 
and to compare the toxicity patterns of EDX and MTX. The trial was 
started as a randomized phase II study with the intention to continue 
as a phase III trial if a potential advantage for EDX was observed.
The sample size calculation for the phase II part of the trial was 
based on a two-stage Gehan’s m ethod12 with the aim to include 20 
patients in each arm and then add five patients for each response 
observed in the first stage. This guarantees that the probability of an 
active treatment (real response rate >  20%) exhibiting no response in 
the first 20 patients (ie false-negative result) is 0.01 and the probabil­
ity of an inactive treatment (real response rate < 5 % )  showing four 
responses (20%) in the first 20 patients is 0.0 1 .
It was decided a priori that if the EDX arm fulfilled these criteria, 
the drug should be considered active enough to continue in a  compar­
ative phase III study against the standard MTX treatment. Case 
record forms were analyzed by the study coordinator every 4 months. 
By the end of the phase II part, the response rate in the M TX arm 
was approximately 15%. To detect an improvement in response rate 
from 15% in the standard arm to 30% in the experimental arm with 
a two-sided type I error of 0.05 and a power of 80%, it was estimated 
that 134 patients should be randomized to each treatment a rm .13
Randomization was centralized in the EORTC Data Center in 
Brussels. During randomization, patients were stratified by institu­
tion at which treatment took place, by site of origin of the tumor, 
and by previous treatment (none, surgery and/or radiotherapy, and 
induction chemotherapy before locoregional treatment). Only pa­
tients with tumors that originated in the oral cavity, oropharynx, 
hypopharynx, or larynx were included. Patients with nasopharyngeal 
tumors or tumors of the maxillary or frontal sinuses were not in­
cluded, since these tumors tend to have a different behavior.2 Strati­
fication was performed using the Pocock minimization technique.
Duration of survival curves were estimated using the Kaplan- 
Meier technique.14 Differences in survival duration were compared 
using a two-sided log-rank test.15 T o  adjust for any confounding 
variables and to assess the relative importance of the potential prog­
nostic factors, C ox’s proportional hazards regression model16 was 
used. Response rates were compared using the Cox logistic regres­
sion model. Analyses were based on all eligible patients according 
to an intent-to-treat policy irrespective of treatment compliance.
RESULTS
Between March 1988 and March 1992, 273 patients 
from 13 institutions were randomized. Nine patients (six 
EDX and three MTX) were deemed ineligible for the 
following reasons: inadequate kidney function (n =  1), 
second tumor (n =  4), poor physical condition (n =  1), 
prior chemotherapy (n =  1), and nasopharyngeal tumor 
(n =  2). Of 264 eligible patients, 85% in the EDX group 
and 84% in the MTX group had at least one measurable 
lesion. Pretreatment characteristics of the 264 eligible 
patients are listed in Table 1. The treatment arms were
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Table 1. Patient and Tumor Characteristics at Entry by Treatment
Group (all eligible patients)
EDX MTX
(n = 131) (n = 133)
Characteristic No. % No. %
Sex
Male 116 89 113 85
Female 15 11 20 15
Karnofsky performance status
50-60 8 6 ó 5
70-80 63 48 65 49
90-100 60 46 62 47
Prior surgery
None 27 21 34 25
Curative 92 70 86 65
Palliative n 8 12 9
Missing data 1 1 1 1
Prior radiotherapy
None 9 7 8 6
Curative 106 81 109 82
Palliative 16 12 1 ó 12
Primary tumor site
Oral cavity 43 33 43 32
Oropharynx 27 21 28 21
Hypopharynx 21 16 16 12
Larynx 40 30 41 31
Other 0 0 5 4
well balanced for all evaluated characteristics. Forty-eight 
percent of the patients had a Karnofsky score of 70 or 
80, and 46% of 90 or 100. Ninety-three percent of patients 
had received prior radiotherapy with either curative (81%) 
or palliative (12%) intent. Sixty-two percent o f  patients 
had locoregional disease only, and 38% had metastatic 
disease with or without locoregional recurrence. Six per­
cent were newly diagnosed with distant metastases.
Treatment
Three of 264 eligible patients refused treatment after ran­
domization and did not receive any chemotherapy. Thirty- 
seven percent of patients received between one and five 
weekly injections of either drag, while 62% received six or 
more. Numbers of courses per treatment arm are listed in 
Table 2. Doses were escalated in 36% of patients on the 
EDX arm and in 45% of patients on the MTX arm. These 
figures did not change after the dose of EDX had been 
reduced to 70 mg/m2. The mean maximum dose of EDX 
given before reduction was 85 mg/m2 (range, 60 to 105) 
and after dose reduction was 75 mg/m2 (range, 64 to 93). 
The mean maximum dose of MTX was 45 mg/m2 (range, 
38 to 73) throughout the study.
Toxicity
Data on toxicity are available for 256 patients (97%). 
There were five treatment-related deaths: four on ED X
and one on MTX. Three patients treated with EDX died 
of sepsis during grade 4 granulocytopenia. One of these 
patients had an unexpected increase in serum creatinine 
level, which was considered to be the cause of grade 4 
leukopenia. In one other case, the grade 4 toxicity of 
EDX was clearly related to a major protocol violation. 
One patient on MTX died of cerebral hemorrhage during 
grade 4 thrombocytopenia. One patient died 3 days after 
the first injection of EDX and on autopsy was found to 
have bilateral pneumonia. Review of the case history of 
this patient showed that it was most likely that he was 
already suffering from pneumonia when EDX was
started.
In general, hematologic toxicity was acceptable and 
rapidly reversible. Details of hematologic toxicity are 
listed in Table 3, Before the dose modification of EDX, 
20% of patients experienced grade 3 to 4 granulocyto­
penia and 8% grade 3 to 4 thrombocytopenia. After dose 
modification, these figures were 15% and 4%, respec­
tively, Interestingly, after dose reduction of EDX, a simi­
lar decrease in hematologic toxicity was observed in both 
treatment arms. Nonhematologic toxicity and other side 
effects were comparable in the two periods. However, 
treatment-related deaths, were only observed before dose 
reduction, except for the patient with a protocol violation.
Nonhematologic toxicity consisted mainly of stomati­
tis, gastrointestinal toxicity such as nausea, vomiting, and 
diarrhea, and skin toxicity. Toxicity details are listed in 
Table 4. In general, the pattern of toxicity was similar in 
both arms, but stomatitis and skin toxicity were more 
pronounced for EDX than for MTX. Particularly, skin 
toxicity was significantly more frequent after EDX than 
after MTX (P <  .0015).
Three cardiac events have been reported, two in the 
EDX-treated group and one in the MTX-treated group. 
One of these was a grade 4 event on the EDX arm, and 
refers to circulatory shock in a patient who died of sepsis 
in grade 4 granulocytopenia. The two other events were 
reversible minor reductions in blood pressure.





(n -  133)
No. % No. %
Treatment never started 2 2 1 1
1-5 46 35 51 38
6-10 39 30 28 21
11-15 31 24 35 26
8 6 12 9
>  20 5 4 ó 5
NOTE. Kruskal-Wallis P -  .023.
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Table 3. Hematologic Toxicity by Treatment Group According
to WHO Scale
EDX MTX
(n — 131 ) (n = 133)
Patient Group No. % No. %
All eligible patients 
Leukopenia (grade)
0 54 41 77 58
1-2 51 39 36 27
3-4 23 18 13 10
Missing data 3 2 7 5
Thrombocytopenia (grade)
0 104 79 117 88
1-2 16 12 5 4
3-4 8 6 4 3
Missing data 3 2 7 5
Eligible patients randomized before dose
modification 60 62
Leukopenia (grade)
0 20 33 30 48
1-2 26 43 20 32
3-4 12 20 10 16
Missing data 2 3 2 3
Thrombocytopenia (grade)
0 45 75 53 85
1-2 8 13 4 6
3-4 5 8 3 5
Missing data 2 3 2 3
Eligible patients randomized after dose
modification 71 71
Leukopenia (grade)
0 34 48 47 66
1-2 25 35 10 23
3-4 11 15 3 4
Missing data 1 1 5 7
Thrombocytopenia (grade)
0 59 83 64 90
1-2 8 11 1 1
3-4 3 4 1 1
Missing data 1 2 5 7
Six pulmonary events were observed on the EDX arm 
and four on the MTX arm. Two patients treated with EDX 
developed septic shock during grade 4 neutropenia and died 
of adult respiratory distress syndrome. For both patients, 
grade 4 pulmonary toxicity was scored. Four other patients 
experienced grade 1 pulmonary toxicity following EDX 
treatment, which was reversible in all cases and was not 
observed again on rechallenge with EDX. In none of these 
cases was a dose reduction necessary, and no delay or medi­
cal treatment was required. In three patients on the MTX 
arm, grade 3 pulmonary toxicity was recorded, which ap­
peared to be bronchial infection. One other patient had re­
versible grade 2 pulmonary toxicity that did not require any 
delays or medication. Subsequent treatment with a 10% 
reduced dose was uneventful.
Reversible elevations in liver transaminases were ob­
served on both arms.
Response and Survival
All eligible patients were included in the analyses of 
response and survival. Twenty-two patients (8.3%) were 
not assessable for response for various reasons, which 
included insufficient number of courses (equal for both 
arms), loss to follow-up evaluation, inability to assess 
properly response, and lack of data. Response data are 
listed in Table 5. There were six CRs and 21 PRs on the 
EDX arm and nine CRs and 12 PRs on the MTX arm. 
Thus, the overall response rate (CRs plus PRs) was 21% 
(95% confidence interval [Cl], 14% to 28%) for EDX 
and 16% for MTX (95% Cl, 10% to 22%) (P = .392).
If patients with an unknown response and nonassessable 
patients are excluded, the response rates are 23% (95% 
Cl, 15% to 30%) and 17% (95% Cl, 10% to 24%) for 
the EDX and MTX arms, respectively (P = .350). The 
median response duration was 6.1 (months) for EDX and 
6.4 months for MTX (log-rank P = .262).
The majority of responses were seen in patients with 
locoregional disease (35 of 164, 21%; 95% Cl, 16% to 
28%) as opposed to metastatic disease (13 of 100, 13%; 
95% Cl, 8% to 21%), and although the difference is 
not statistically significant, there is a trend in favor of 
locoregional disease. In patients with hypopharynx can­
cer, significantly fewer responses (P = 0.026, x~ test) 
were observed than in patients with tumors that originated 
from the larynx, oral cavity, or oropharynx. Using the 
multivariate logistic regression model, no other variables 
were found to be statistically significant.
A multivariate analysis based on the Cox proportional 
hazards regression model was performed to test for treat­
ment effect when adjusted for the parameters extent of 
disease, primary tumor site, sex, and Karnofsky index, 
and to assess their relative importance with respect to 
survival. The treatment effect was not statistically sig­
nificant when these variables were taken into account. 
Only extent of disease was significantly related to sur­
vival; patients with metastatic disease had a relative risk 
of 1.4 (95% Cl, 1.0 to 2.0; P =  .006) when compared 
with patients with locoregional disease.
There was no significant difference in overall or pro­
gression-free survival (Fig 1).
DISCUSSION
This randomized phase III study confirmed that EDX 
is an active drug in the treatment of patients with meta­
static or recurrent SCC, but demonstrated that there is no 
difference between EDX and MTX in terms of response
Table 4. Nonhematologic Toxicities
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Grade
EDX* (n = 131) MTXt (n = 133)
0 1-2 3-4 0 1-2 3-4
Variable Toxicity No. % No. % No. % No. % No. % No. %
Stomatitis 36 27 69 53 24 18 77 58 39 29 11 8
Nausea/vomiting 68 52 57 44 4 3 72 54 51 38 4 3
Liver, transaminases 95 73 26 20 8 6 104 78 16 12 7 5
Cutaneous 92 70 28 21 9 7 121 91 5 4 1 1
Diarrhea 113 86 15 11 1 1 111 83 16 12
Infection 113 86 13 10 3 2 116 87 11 8
Alopecia 115 88 13 10 1 1 118 89 9 7
Drug fever 119 91 10 8 114 86 13 10
Neurologic 121 92 7 5 1 1 117 88 9 7 1 1
Pulmonary 124 95 4 3 1 1 123 92 2 2 2 2
Local/phlebitis 125 95 4 3 126 95 1 1
Renal, creatinine 127 97 2 2 125 94 2 2
Cardiac 127 97 1 1 1 1 126 95 1 1
Allergy 127 97 2 2 125 94 2 2
Othert 84 64 39 30 6 5 92 69 34 26 1 1
‘ Missing data/unknown, n = 2; 129 assessable patients. 
tMissing data/unknown, n = 6; 127 assessable patients, 
f  Anorexia, tiredness.
rate, response duration, or survival duration. Before dose 
reduction of EDX, 13 of 60 (22%) responses (CRs plus 
PRs) were observed, versus 14 of 71 (20%) after dose 
modification, which indicates that the dose reduction was 
not associated with reduced activity. This would be in 
concert with the fact that high-dose MTX has never been 
demonstrated to be superior to conventional-dose M TX 
in head and neck cancer.17 The hematologic toxicity of 
EDX appeared to be acceptable, although 18% of patients 
experienced grade 3 to 4 granulocytopenia. Three of these 
patients died of septicemia. On retrospective analysis, it 
appeal's most likely that EDX alone was responsible for 
the cases of grade 4 toxicity, since this level or toxicity 
was not associated with concomitant medication, which 
may enhance the serum levels or inhibit the excretion of







No. % No. %
CR 6 5 9 7
PR 21 16 12 9
No change 36 27 41 31
Progression 48 37 52 39




Unknown or not assessable 11 9 9 8
drugs such as MTX and structural analogs. An interesting 
observation was that following the dose reduction of only 
EDX, the hematologic toxicity of both EDX and M TX 
improved. There is no apparent explanation for this, since 
the dose of MTX was the same throughout the study. 
A possible explanation could be increased investigator 
awareness of the risks of both drugs. The general pattern 
of toxicity of EDX is similar to that of MTX, but EDX 
was associated with more mucositis and significantly 
more skin toxicity. Somewhat unexpected was the high 
incidence (28%) of a characteristic form of skin toxicity 
of EDX, This consisted of painless, occasionally pruritic, 
skin lesions not associated with other systemic symptoms 
such as allergic reactions. The skin lesions were progres­
sive on continuation of EDX, but resolved completely 
when the drug was discontinued or with small doses of 
prednisone. Histologically, it appeared to be a toxic der­
matitis. The skin toxicity, which is distinct from the rash 
commonly associated with MTX, has been described in 
detail elsewhere.18 The dose-limiting toxicity of EDX ap­
pears to be stomatitis, which was observed in 71% of 
patients.
M TX has been reported to produce response rates of 
20% to 40% in this category of patients, depending on 
the schedule used.1,2,17,19 A weekly dose of 40 to 50 
m g/m 2 of MTX is considered standard therapy and has 
been found to be as active as high-dose m ethotrex­
ate.2,17 The response rate of 16% in 133 patients treated 
with M TX  is rather disappointing in comparison to the
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(months)
Fig 1. Survival duration of pa­
tients treated with EDX (--------- )
or MTX (----- ); lag-rank P -  .50.
Curves for progression-free sur­
vival (not shown) were also iden­
tical for both groups.
Number of patients at risk :
131 63 27 7 2 2 EDX
133 64 17 8 3 1 MTX
20% to 40% response rate reported in the literature. 
In a similar group of patients, a recently published 
Southwest Oncology Group Study reported only 10% 
objective responses with weekly M TX in 88 patients.20 
As in our group of patients, the majority of those had 
recurrent disease in previously irradiated areas. In view 
of these data, it becomes questionable whether MTX 
should continue to be considered the standard for pal­
liative treatment o f  this group of patients. To establish 
this issue, the EO RTC Head and Neck Cancer Coopera­
tive Group is currently comparing MTX with best sup­
portive care in terms of quality of life and survival in 
a prospective randomized trial.
In the Southwestern Oncology Group study,20 the sur­
vival of the patients was identical among the three groups, 
regardless of treatment arm, even though combination 
chemotherapy with cisplatin and 5-FU had a significantly 
higher response rate. As in our study, the median survival 
duration of all patients was approximately 6 months. Vir­
tually the same survival data were obtained in a previous 
EORTC study, in which cisplatin was compared with two 
cisplatin-containing combination regimens. Although the 
combination regimens had significantly higher response 
rates than single-agent cisplatin, the overall survival 
curves were superimp os able, with a median survival time 
of approximately 6 months.3 Similar results have been 
reported from a large trial (249 patients) comparing cis­
platin plus 5-FU with cisplatin alone and 5-FU alone.21
Although the response rate to the combination (32%) was 
superior to that achieved with single agents, survival was 
not improved. Cisplatin and 5-FU had response rates of 
17% and 13%, respectively, and thus appeared to have 
the same level of activity as MTX. However, the conve­
nience and low cost of weekly administration of MTX in 
combination with its relatively low level of toxicity make 
the latter drug more attractive than the former two com­
pounds. These data indicate that combination chemother“ 
apy should not be standard palliative treatment for pa­
tients with SCC and that further studies on the quality of 
palliation are needed.
In addition to the activity in head and neck cancer, 
EDX is reported to have single-agent activity in non- 
small-cel] lung cancer7,8 and breast cancer.9 A similar 
pattern of toxicity was observed in those studies com­
pared with the current study.
In conclusion, the activity of EDX in the treatment of 
patients with metastatic or recurrent SCC was confirmed 
in this study. However, in view of the fact that EDX was 
not more active against SCC than MTX, but had more 
side effects than the latter drug, EDX cannot be recom­
mended for routine palliative treatment of patients with 
SCC. This study, as well as the SWOG study, suggests 
that the activity of MTX in patients with SCC is less than 
is stated in the literature. New drugs or approaches that 
can improve the survival of this group of patients with 
acceptable toxicity are urgently needed.
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